Imatinib mesylate (Gleevec (TM)) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open-label, extension phase, single-centre trial

导出原文传递

翻译打印收藏纠错

作者： Gordon, J. ^[1] ; Udeh, U. ^[2] ; Doobay, K. ; Magro, C. ; Wildman, H. ; Davids, M. ; Mersten, J. N. ; Huang, W. -T. ; Lyman, S. ; Crow, M. K. ; Spiera, R. F.

作者单位： Hosp Special Surg, New York, NY 10021 USA ^[1] Weill Cornell Med Coll, New York, NY USA ^[2]

关键词 scleroderma systemic sclerosis imatinib fibrosis tyrosine kinase inhibitor

发布时间 2020-02-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical and experimental rheumatology

2014年32卷6 Suppl.86期

S189-S193页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Imatinib mesylate (Gleevec (TM)) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open-label, extension phase, single-centre trial

Clinical and experimental rheumatology

相似文献

Clinical and experimental rheumatology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Imatinib mesylate (Gleevec (TM)) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open-label, extension phase, single-centre trial

Clinical and experimental rheumatology

相似文献

Clinical and experimental rheumatology

相关期刊

检索历史清除